Hemoglobin A1C stability and dementia in older adults with diabetes

The Defense Health Agency awarded Boston VA Research Institute, Inc. $997,393 on July 1, 2026, under the Military Medical Research and Development program (CFDA 12.420) to investigate hemoglobin A1C stability and dementia in older adults with diabetes. The project runs through June 30, 2029, with performance at Boston, Massachusetts.

The research examines the relationship between glycemic control variability, as measured by hemoglobin A1C stability, and dementia risk in an aging diabetic population, likely drawing on veteran patient cohorts and clinical data infrastructure at VA Boston Healthcare System. Boston VA Research Institute operates as a nonprofit research institute affiliated with the VA, positioning the work within the Defense Health Agency's focus on biomedical research to improve health outcomes for Service Members and veteran populations. The award reflects the program's typical three- to four-year project grant structure for hypothesis-driven translational and clinical research.